Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma.
作者信息
Goodman Rachel S, Justice Joy, Gardner Laura J, Singh Reena, Dewan Anna K, Johnson Douglas B
机构信息
Vanderbilt University School of Medicine, Nashville, Tennessee, US.
Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, US.
出版信息
Eur J Cancer. 2023 Oct;192:113255. doi: 10.1016/j.ejca.2023.113255. Epub 2023 Aug 16.
Abstract
摘要
相似文献
1
Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma.III 期黑色素瘤辅助抗程序性死亡蛋白 1（PD-1）治疗的迟发性和持续性多系统毒性
Eur J Cancer. 2023 Oct;192:113255. doi: 10.1016/j.ejca.2023.113255. Epub 2023 Aug 16.
2
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.COLUMBUS-AD：恩考芬尼+比美替尼辅助治疗IIB/IIC期BRAF V600突变型黑色素瘤的III期研究。
Future Oncol. 2023 Sep;19(30):2017-2027. doi: 10.2217/fon-2023-0414. Epub 2023 Sep 4.
3
Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.中国单中心真实世界回顾性研究比较分析 III 期 BRAF 突变黑色素瘤的辅助治疗。
Cancer Med. 2023 May;12(10):11475-11482. doi: 10.1002/cam4.5866. Epub 2023 Apr 4.
4
Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.辅助 PD-1 抑制剂对比大剂量干扰素 α-2b 治疗中国皮肤及肢端黑色素瘤患者：一项回顾性队列分析。
Dermatol Ther. 2021 Sep;34(5):e15067. doi: 10.1111/dth.15067. Epub 2021 Jul 29.
5
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.辅助用伊匹单抗（3 或 10 mg/kg）对比高剂量干扰素 α-2b 用于切除的高风险黑色素瘤的 III 期研究：北美协作组 E1609。
J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27.
6
Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?辅助免疫疗法在 III 期黑色素瘤中的时机选择，重要吗？
Ann Surg Oncol. 2023 Oct;30(11):6340-6352. doi: 10.1245/s10434-023-13935-0. Epub 2023 Jul 22.
7
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.新辅助帕博利珠单抗治疗可切除 III/IV 期皮肤黑色素瘤患者的病理缓解的长期结果。
Ann Oncol. 2023 Sep;34(9):806-812. doi: 10.1016/j.annonc.2023.06.006. Epub 2023 Jul 4.
8
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.转移性肢端、黏膜和葡萄膜黑色素瘤使用检查点抑制剂后的生存情况。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000341.
9
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.辅助治疗肢端黑色素瘤中的抗 PD-1：一项全国性研究。
Int J Cancer. 2024 Oct 15;155(8):1455-1465. doi: 10.1002/ijc.35060. Epub 2024 Jun 24.
10
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.不可切除转移性皮肤黑色素瘤中免疫检查点靶向治疗：抗CTLA-4和抗PD-1药物试验的系统评价和荟萃分析
Cancer Med. 2016 Jul;5(7):1481-91. doi: 10.1002/cam4.732. Epub 2016 May 11.
本文引用的文献
1
Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab.英夫利昔单抗成功治疗程序性死亡受体1抑制剂诱导的银屑病。
J Eur Acad Dermatol Venereol. 2023 May;37(5):e621-e623. doi: 10.1111/jdv.18780. Epub 2022 Nov 30.
2
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.免疫介导性腹泻和结肠炎在癌症患者中的 vedolizumab 和英夫利昔单抗治疗的疗效和安全性：一项两中心观察性研究。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003277.
3
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
4
Immunotherapy-related gastritis: Two case reports and literature review.免疫治疗相关胃炎：两例病例报告及文献综述
Clin Med Insights Oncol. 2021 Jul 9;15:11795549211028570. doi: 10.1177/11795549211028570. eCollection 2021.
5
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.黑色素瘤中基于抗PD-1免疫疗法的延迟性免疫相关不良事件。
Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30.
6
Oral mucositis-case series of a rare adverse effect associated with immunotherapy.口腔黏膜炎病例系列：一种与免疫疗法相关的罕见不良反应。
Support Care Cancer. 2021 Aug;29(8):4705-4709. doi: 10.1007/s00520-021-05993-5. Epub 2021 Jan 29.
7
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.纳武利尤单抗对比安慰剂作为黑色素瘤辅助治疗的间接治疗比较。
Eur J Cancer. 2020 Jun;132:176-186. doi: 10.1016/j.ejca.2020.03.011. Epub 2020 May 4.
8
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
9
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
10
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.抗程序性死亡蛋白1（PD-1）疗法的皮肤、胃肠道、肝脏、内分泌及肾脏副作用。
Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.
Zotero 插件